7 unknown. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Unknown 7 |
| Phase 2 | 2 | Unknown 2 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis MD1003 100mg capsule - Multiple Sclerosis | Phase 3 | Unknown | MedDay Pharmaceuticals SA | 105 | 2013-10-01 | 2017-03-27 |
| Bupivacaine Injection of Eye Muscles to Treat Strabismus Bupivacaine - Strabismus, Esotropia | Phase 2 / Phase 3 | Unknown | Smith-Kettlewell Eye Research Institute | 120 | 2012-04-01 | 2019-09-23 |
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception tasimelteon - Non 24 Hour Sleep Wake Disorder | Phase 3 | Unknown | Vanda Pharmaceuticals | 140 | 2010-10-28 | 2024-04-03 |
| Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab bevacizumab, ranibizumab - Age-Related Neovascular Macular Degeneration | Phase 3 | Unknown | Klinikum Bremen-Mitte, gGmbH | 366 | 2008-08-01 | 2009-03-26 |
| Atorvastatin for the Treatment of Retinal Vein Occlusion Atorvastatin, Placebo - Retinal Vein Occlusion, Retinal Vein Thrombosis | Phase 3 | Unknown | University of Toronto | 180 | 2007-08-01 | 2008-06-25 |
| Vision In Preschoolers Study (VIP Study) Vision Screening - Amblyopia, Strabismus | Phase 3 | Unknown | National Eye Institute (NEI) | 2009-10-16 |
Blindness (2) · Eye Diseases (2) · Strabismus (2) · Amblyopia (1) · Blepharoptosis (1) · Chronobiology Disorders (1) · Diplopia (1) · Dyssomnias (1) · Esotropia (1) · Exotropia (1) · Eye Abnormalities (1) · Graves Disease (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1)
Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Sensation Disorders (6) · Eye Diseases (5) · Cranial Nerve Diseases (3) · Autoimmune Diseases (2) · Immune System Diseases (2) · Ocular Motility Disorders (2) · Pathologic Processes (2) · Retinal Diseases (2) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1)
Atorvastatin (1) · Bevacizumab (1) · Bupivacaine (1) · Ranibizumab (1) · Vision Screening (1) · tasimelteon (1)
Klinikum Bremen-Mitte, gGmbH (1) · MedDay Pharmaceuticals SA (1) · National Eye Institute (NEI) (1) · ProQR Therapeutics (1) · Smith-Kettlewell Eye Research Institute (1) · University of Toronto (1) · Vanda Pharmaceuticals (1)
Canada (2) · France (2) · Germany (2) · United Kingdom (2) · United States (2) · Belgium (1) · Brazil (1) · Italy (1) · Netherlands (1)
Alan B Scott, MD (1) · Ayman Tourbah, MD, PhD (1) · Bernd Muehlbauer, Professor MD (1) · David Wong, MD (1) · Frederic Sedel, MD, PhD (1) · Joel G Ray, MD MSc (1) · Joel M Miller, PhD (1)